Matera

Researchers are evaluating the efficacy and safety of Afimkibart also known as RO7790121 as an induction therapy in people aged 16 to 80 with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to compare Afimkibart with placebo to understand its potential benefits and risks for this condition. Participants will be randomly assigned to receive either Afimkibart through an intravenous infusion followed by a subcutaneous injection, or a placebo infusion followed by Afimkibart subcutaneous injection. The study treatment is given to assess the impact on Crohns disease activity over a 12-week period. During the study, participants will have their symptoms and disease activity monitored using assessments like the Crohns Disease Activity Index CDAI, endoscopic evaluations, stool and abdominal pain tracking, and quality of life questionnaires. Safety will be closely observed up to 30 weeks after starting treatment. This study helps to measure remission rates and responses to treatment over time.

This research aims to evaluate the effects of adding Vitamin D supplementation to standard immunochemotherapy in elderly patients diagnosed with Diffuse Large B-Cell Lymphoma or Follicular grade IIIb lymphoma. This open-label, randomized phase III trial compares two treatment approaches to understand whether Vitamin D affects outcomes in patients aged 65 and older undergoing immunochemotherapy. Participants are randomly assigned to one of two groups. Both groups receive a prephase of oral prednisone followed by six cycles of immunochemotherapy with R-CHOP or R-miniCHOP every 21 days. The experimental group also receives Vitamin D supplementation starting before treatment and continuing through immunochemotherapy according to a set schedule, including loading doses based on baseline Vitamin D levels and weekly maintenance. Patients may continue Vitamin D supplementation after treatment for up to two years. During the study, participants undergo baseline assessments and are monitored regularly through the treatment cycles. Researchers track progression-free survival over 54 months as the primary outcome, along with overall survival, response rates, Vitamin D levels, physical functioning, and fatigue. Safety and treatment adherence are also monitored, with follow-up visits extending up to several years to evaluate long-term outcomes.

This research aims to understand how diets enriched with polyunsaturated fatty acids PUFAs from animal or plant sources affect chronic inflammation linked to cardiovascular disease risk. The study focuses on adults over 55 years old at moderate to high cardiovascular risk, comparing the impact of these diets on a lipid and inflammation-based risk score. It also explores how these dietary changes might improve blood lipid, sugar, and inflammation markers while promoting public awareness of inflammation as a modifiable risk factor. Participants will be randomly assigned to one of three groups a daily fish oil supplement providing specific amounts of DHA and EPA, a daily vegetable oil supplement Camelina Sativa Oil rich in alpha-linolenic acid plus vitamin E, or a regular diet with vitamin E only. These supplements will be taken as liquid oils for 12 weeks, with vitamin E added to balance antioxidant intake between groups. The vegetable oil dose equals about 1500 mg of n-3 PUFAs daily, while fish oil provides slightly higher amounts. During the study, participants will have clinical visits at the start and after 12 weeks, including blood sample collection for fatty acid and biomarker analysis. Researchers will also measure heart rate, blood pressure, waist circumference, and collect dietary information through questionnaires. The main measure is a lipid and inflammation risk score derived from blood tests, and the study will evaluate how well participants accept the dietary supplements. Data from compliant participants will be analyzed to assess the effects of these dietary strategies on chronic inflammation related to cardiovascular health.